Allogene Therapeutics (ALLO) Aktievy
Allogene Therapeutics, Inc. är ett immunonkologibolag i klinisk fas som utvecklar och kommersialiserar genetiskt modifierade allogena T-cellsterapier för behandling av cancer och autoimmuna sjukdomar. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
+ 1 större risk
ALLO Community Fair Values
Create NarrativeSee what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Allogene Therapeutics, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$1.96 |
| 52 veckors högsta | US$4.46 |
| 52 veckors lägsta | US$0.98 |
| Beta | 0.46 |
| 1 månads förändring | -15.52% |
| 3 månaders förändring | -4.39% |
| 1 års förändring | 79.82% |
| 3 års förändring | -64.17% |
| 5 års förändring | -92.08% |
| Förändring sedan börsintroduktionen | -92.16% |
Senaste nyheter och uppdateringar
Recent updates
Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL
Summary Allogene Therapeutics is positioned for a paradigm shift in CAR T therapy with cema-cel, targeting earlier, scalable intervention in high-risk LBCL. ALPHA3 interim data showed 58.3% MRD negativity for cema-cel versus 16.7% for observation, with a notably clean safety profile and outpatient feasibility. ALLO's sub-$500M enterprise value suggests the market is only partially pricing in the platform's potential, despite a sharp post-data rally. I maintain a long-term buy rating, expecting future EFS readouts to confirm Cema-Cel's best-in-class potential, though near-term volatility is likely. Read the full article on Seeking AlphaWill Allogene Therapeutics (NASDAQ:ALLO) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. By way of example, Allogene...
MRD Guided Cell Therapy And Autoimmune Focus Will Transform Long Term Opportunity
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?
Off The Shelf CAR T Therapies Will Reshape Lymphoma And Autoimmune Treatment Trajectories
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?
Allogeneic CAR T Expectations Will Likely Disappoint As Trial And Cash Runway Risks Mount
Catalysts About Allogene Therapeutics Allogene Therapeutics is a biotechnology company focused on developing off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now
Key Insights Allogene Therapeutics to hold its Annual General Meeting on 18th of June Salary of US$724.0k is part of...Here's Why We're Watching Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Summary Allogene Therapeutics appears undervalued despite market skepticism, with a robust cash runway and potential breakthroughs in allogeneic CAR-T therapies. The company's lead asset, cema-cel, aims to shift CAR-T therapy to early intervention, potentially expanding its market and redefining treatment standards. ALLO-329 targets autoimmune diseases, positioning Allogene in a new market with significant unmet needs and less competition compared to oncology. Key risks include the efficacy and durability of allogeneic CAR-T therapies and manufacturing consistency, but early data and strategic positioning offer compelling upside potential. Read the full article on Seeking AlphaAllogene Therapeutics: Showing Promise Despite Some Shaky Safety
Summary Allogene is among the pioneers in non-self engineered cell therapy. They have demonstrated encouraging early results in lymphoma, moving aggressively into a pivotal trial in the first-line setting. Their pivotal phase 2 trial ALPHA3 has the potential to change how large B-cell lymphoma is managed, but we won't have these results until 2026. Other projects, like their CD70-directed therapy, look promising but have concerning safety signals, and they're also a long way from approval. Read the full article on Seeking AlphaIs Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
Summary Allogene Therapeutics is a clinical-stage biotech developing allogeneic CAR T therapies for cancer and autoimmune diseases, with a focus on Cema-cel for LBCL. ALLO's advanced gene-editing platforms, like TALEN and CRISPR/Cas9, engineer donor-derived T cells to overcome autologous therapy limitations, enhancing treatment safety and effectiveness. Cema-cel, the company’s flagship therapy, is in a pivotal Phase 2 trial (ALPHA3) for large B-cell lymphoma, with potential regulatory submission by 2027. Despite a promising pipeline, ALLO faces cash runway concerns, making it a suitable DCA “buy” for investors aware of clinical trial risks. ALLO's valuation is attractive, with a low P/B multiple and sufficient liquidity to fund operations until the ALPHA3 trial's primary data readout in 2026. Read the full article on Seeking AlphaAllogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Summary Allogene Therapeutics, Inc. initiation of phase 2 ALPHA3 study, using cema-cel for the treatment of patients with 1st-line large B-cell lymphoma, expected in mid-2024 with two data analysis in 2026. Results from phase 2 ALPHA2 trial, using cema-cel for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia, expected by end of 2024. Results from phase 1 TRAVERSE trial, using ALLO-316 for the treatment of CD70 positive clear cell renal cell carcinoma patients, expected by the end of 2024. Company gained rights from Servier to expand use of cema-cel for r/r CLL and 1st-line LBCL in European and U.K. territories; New potential to tap into >$9.5 billion market opportunity if approval is achieved for these indications. Read the full article on Seeking AlphaWe Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
Key Insights Allogene Therapeutics to hold its Annual General Meeting on 5th of June Total pay for CEO David Chang...Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Summary Allogene Therapeutics has announced changes to its pipeline that extend its financial runway into 2026. The new ALPHA3 clinical trial for Allogene's Cema-Cel cancer treatment is set to begin in mid-2024, and if successful, investors could see significant returns on their investment. The company's Q42023 report evidenced its financial distress. However, the 2024 platform vision, in my opinion, will have a positive impact on its profitability in the midterm. Given the lack of short-term revenue catalysts, with clinical trials expected to yield results by the end of 2024, investors will be required to be patient, while experiencing high volatility and potential share dilutions this year. Read the full article on Seeking AlphaWe Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Aktieägarnas avkastning
| ALLO | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | -8.4% | -3.0% | -0.3% |
| 1Y | 79.8% | 32.9% | 26.7% |
Avkastning vs industri: ALLO översteg US Biotechs branschen som gav 32.9 % under det senaste året.
Avkastning vs Marknaden: ALLO översteg US marknaden som gav 26.7 % under det senaste året.
Prisvolatilitet
| ALLO volatility | |
|---|---|
| ALLO Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: ALLO s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: ALLO s veckovolatilitet ( 15% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2017 | 151 | David Chang | allogene.com |
Allogene Therapeutics, Inc. är ett immunonkologibolag i klinisk fas som utvecklar och kommersialiserar genetiskt modifierade allogena T-cellsterapier för behandling av cancer och autoimmuna sjukdomar. Bolaget utvecklar en pipeline med flera allogena CAR T-cellsproduktkandidater med hjälp av protein engineering, genredigering, geninsättning och avancerad patentskyddad teknik för tillverkning av T-celler. Bolaget utvecklar också cemacabtagene ansegedleucel (cema-cel), en allogen CAR T-cells produktkandidat som riktar in sig på CD19 för behandling av storcelligt B-cellslymfom (LBCL).
Allogene Therapeutics, Inc. Sammanfattning av grunderna
| ALLO grundläggande statistik | |
|---|---|
| Börsvärde | US$655.79m |
| Vinst(TTM) | -US$173.76m |
| Intäkter(TTM) | n/a |
Är ALLO övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ALLO resultaträkning (TTM) | |
|---|---|
| Intäkter | US$0 |
| Kostnad för intäkter | US$131.96m |
| Bruttovinst | -US$131.95m |
| Övriga kostnader | US$41.81m |
| Intäkter | -US$173.76m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.50 |
| Bruttomarginal | 0.00% |
| Nettovinstmarginal | 0.00% |
| Skuld/egenkapitalförhållande | 0% |
Hur har ALLO utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/21 23:41 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Allogene Therapeutics, Inc. bevakas av 31 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jack Allen | Baird |
| Shanshan Xu | Berenberg |
| William Pickering | Bernstein |